Tricida’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Tricida is a biopharmaceutical company that develops novel therapeutics for the treatment of renal, metabolic and cardiovascular diseases. Read more

Tricida is a biopharmaceutical company that develops novel therapeutics for the treatment of renal, metabolic and cardiovascular diseases. Read more

Gerrit Klaerner's photo - President & CEO of Tricida

President & CEO

Gerrit Klaerner

CEO Approval Rating

90/100

Founded:

2013

Status:

PublicNASDAQTCDA

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Akebia Therapeutics, Inc. is the biggest rival of Tricida. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, and was founded in 2007. Like Tricida, Akebia Therapeutics, Inc. also operates in the Biotechnology space. Akebia Therapeutics, Inc. generates ∞% the revenue of Tricida.

Angion is Tricida's #2 competitor. Angion is a Private company that was founded in San Francisco, California in 1998. Like Tricida, Angion also works within the Biotechnology sector. Angion has 41 fewer employees vs. Tricida.

Resverlogix has been one of Tricida's top competitors. Resverlogix's headquarters is in Calgary, Alberta, and was founded in 2001. Resverlogix operates in the Pharmaceuticals industry. Resverlogix generates ∞% of Tricida's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Keryx a competitor of Tricida?

Quarterly and Annual Revenue

Coming soon for Tricida!

Annual Revenue

Acquisitions

No recent acquisitions found related to Tricida

Tricida Funding History

$4.5M$14.5M$31.7M$55.6M$113.1M$435.4M$610.4M

Since Tricida was founded in 2013, it has participated in 8 rounds of funding. In total Tricida has raised $610.4M. Tricida's last funding round was on May 2020 for a total of $175.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
May 2020
$175M
-
IPO
Jun 2018
$222.3M
-
Debt
Mar 2018
$100M
Series D
Nov 2017
$57.6M
Series C
Jul 2016
$23.9M

Total Funding: $610.4M

Since Tricida was founded in 2013, it has participated in 8 rounds of funding. In total Tricida has raised $610.4M. Tricida's last funding round was on May 2020 for a total of $175.0M

Investments

No recent investments found related to Tricida

Tricida News

October 4, 2020Zolmax News

Genprex (NASDAQ:GNPX) versus Tricida (NASDAQ:TCDA)

Tricida (NASDAQ:TCDA) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is th... See more »
September 25, 2020Zolmax News

-$1.07 EPS Expected for Tricida Inc (NASDAQ:TCDA) This Quarter

Brokerages expect Tricida Inc (NASDAQ:TCDA) to announce earnings per share of ($1.07) for the current... See more »
September 2, 2020Zolmax News

Brokerages Anticipate Tricida Inc (NASDAQ:TCDA) Will Announce Earnings of -$1.07 Per Share

Wall Street analysts expect that Tricida Inc (NASDAQ:TCDA) will post ($1.07) earnings per share (EPS)... See more »
September 1, 2020Benzinga

Bragar Eagel & Squire, P.C. is Investigating Tricida, Inc. on Behalf of Tricida Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shar... See more »
August 29, 2020MarketScreener

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Tricida, Inc. - TCDA

(marketscreener.com) NEW YORK, Aug. 29, 2020 -- Rosen Law Firm, a global investor rights law firm, an... See more »
August 25, 2020The Pharma Letter

Longer road ahead for kidney disease candidate

Shares in San Franciscan biotech Tricida fell by a quarter on Monday, after the firm announced the US... See more »

Tricida Press Releases

September 12, 2019Business Wire

Tricida Launches Metabolic Acidosis Insights, an Online Educational Resource for the Healthcare Community

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New website offers metabolic acidosis disease awareness... See more »
January 4, 2017Blackbird

Tricida to Present at 35th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Tricida, Inc. today announced that its management will be... See more »
March 4, 2015BUSINESS WIRE

Tricida Announces Closing of $30M Series B Financing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc., closes $30M Series B financing; raises s... See more »
September 4, 2014BUSINESS WIRE

Tricida Announces In-House Discovered Clinical Candidate in Cardiorenal Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida announces discovery of a clinical candidate for... See more »

Headquarters

7000 Shoreline Court Suite 201

South San Francisco, California94080

1-415-429-7800

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Tricida is a biopharmaceutical company that develops novel therapeutics for the treatment of renal, metabolic and cardiovascular diseases. Tricida was founded in 2013. Tricida's headquarters is located in South San Francisco, California, USA 94080. It...

CEO

Tricida's President & CEO, Gerrit Klaerner, currently has an approval rating of 90%. Tricida's primary competitors are Akebia Therapeutics, Inc., Angion & Resverlogix.

Website

tricida.com

Frequently Asked Questions about Tricida

  1. When was Tricida founded?

    Tricida was founded in 2013
  2. Who is Tricida's CEO?

    Tricida's CEO is Gerrit Klaerner
  3. How much revenue does Tricida generate?

    Tricida generates $ < 1M in revenue
  4. How much funding does Tricida have?

    Tricida has historically raised $610.4M in funding
  1. Where is Tricida's headquarters?

    Tricida's headquarters is in South San Francisco California, USA
  2. How many employees does Tricida have?

    Tricida has 76 employees
  3. What sector does Tricida operate in?

    Tricida is in Biotechnology, Pharmaceuticals
  4. Who are Tricida's competitors?

    Tricida's top competitors are Akebia Therapeutics, Inc., Angion, Resverlogix